Xlife Sciences AG (XLS)

Overview

Xlife Sciences AG is a dynamic company operating within the life sciences sector, dedicated to the development and commercialization of innovative technologies. Based in Zurich, Switzerland, the company's mission is to leverage cutting-edge scientific discoveries to address some of the most challenging issues in human health. By focusing on the utilization of human genetic data, Xlife Sciences AG aims to uncover novel therapeutic approaches and biomarkers for widespread diseases. In its pursuit to combat life-threatening conditions, particularly cancer, the company is involved in the creation of both mono- and bispecific anti-tumor antibodies. Besides its contributions to oncology, Xlife Sciences AG is also invested in the production of chemical and active pharmaceutical ingredients for a variety of medical and veterinary applications, along with pioneering solutions in the detection and management of kidney diseases and neurodegenerative disorders.

Products and Services

• Technology Platforms for Therapeutic Approaches and Biomarkers

  Utilizing the power of human genetic data, these platforms are at the core of Xlife Sciences AG’s innovation, aimed at discovering new therapeutic methods and biomarkers that address common diseases, paving the way for more personalized and effective treatments.

• Mono-and Bispecific Anti-Tumor Antibodies

  In the fight against cancer, Xlife Sciences AG is developing targeted antibodies. These antibodies are designed to engage and neutralize cancer cells, offering hope for more effective and less toxic cancer therapies.

• Chemicals and Active Pharmaceutical Ingredients (APIs)

  The company supports a wide range of human and veterinary medicines through its research, development, and manufacturing of high-quality chemical substances and active pharmaceutical ingredients, contributing to the health and well-being of both humans and animals.

• Biomarkers for Kidney Diseases

  Identifying biomarkers for kidney diseases is another area of focus for Xlife Sciences AG. These biomarkers can lead to early detection and more targeted treatment strategies, improving patient outcomes in kidney health.

• Functional Screening of Antibodies by Microfluidics

  This innovative approach leverages microfluidic technology for the functional screening of antibodies, streamlining the discovery and development process of new therapeutics.

• Neuromex - Screening Tool for Neurodegenerative Diseases

  Neuromex represents a groundbreaking screening tool developed by Xlife Sciences AG for the early detection of neurodegenerative diseases. This tool aims to transform the management of conditions such as Alzheimer's and Parkinson's disease, offering hope for earlier intervention and therapy optimization.